Dynavax Announces FDA Acceptance for Review of Biologics

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Dynavax Announces FDA Acceptance for Review of Biologics License Application and PDUFA Action Date for HEPLISAV-B(TM)

BERKELEY, CA --(Marketwired - March 30, 2016) -  Dynavax Technologies Corporation ( NASDAQ : DVAX ) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for HEPLISAV-B ™ , the company's vaccine candidate for immunization against hepatitis B infection in adults 18 years of age and older. The FDA has established September 15, 2016 as the Prescription Drug User Fee Act (PDUFA) action date.

"This filing is another important step toward our goal of bringing HEPLISAV-B to market to protect adults against hepatitis B," said Eddie Gray, chief executive officer for Dynavax. "We will continue to work closely with the FDA over the coming months in order to achieve HEPLISAV-B approval in the third quarter of 2016."

The HEPLISAV-B BLA is based on positive immunogenicity results from clinical trials that have generated safety data in more than 10,000 participants. Results of these trials showed that two doses of HEPLISAV-B given one month apart provides significantly higher rates of protection with an equivalent safety profile compared to three doses of Engerix-B, a currently marketed hepatitis B vaccine that is administered over six months. In Phase 3 studies across all participants, HEPLISAV-B achieved peak seroprotection rates of 95.7 percent compared with 79.5 percent for Engerix-B. Additionally, in more than 1,100 participants with diabetes, HEPLISAV-B provided seroprotection rates of 90 percent compared to 65.1 percent for Engerix-B.

"Adult hepatitis B infection remains an important public health concern. If approved, HEPLISAV-B will represent the first advance in hepatitis B immunization in the United States in more than 25 years and will offer rapid protection from hepatitis B after only two doses in just one month," said Robert Janssen, M.D., chief medical officer and vice president, clinical development for Dynavax. "We believe HEPLISAV-B will provide a significant real-world improvement over currently marketed hepatitis B vaccines."

About Hepatitis B

Hepatitis B is a viral disease of the liver that can become chronic and can lead to cirrhosis of the liver, hepatocellular carcinoma and death. In the United States, the Centers for Disease Control and Prevention estimates that 19,000 hepatitis B infections continue to occur annually, with the vast majority occurring in adults. There is no cure for hepatitis B, and disease prevention through more effective vaccines is critical to reducing the spread of the disease.

About HEPLISAV-B ™

HEPLISAV-B ™ is an investigational adult hepatitis B vaccine that combines hepatitis B surface antigen with a proprietary Toll-like Receptor 9 agonist to enhance the immune response. In Phase 3 trials, HEPLISAV-B demonstrated higher and earlier protection with fewer doses than a currently licensed hepatitis B vaccine.

HEPLISAV-B is administered in two doses over one-month, offering rapid protection. Currently marketed hepatitis B vaccines are administered in three doses over a six-month schedule. Results of a published Vaccine Safety Datalink study showed that only 54 percent of adults completed the three-dose hepatitis B vaccine series in one year. 1 Those who do not complete the series may not be adequately protected against hepatitis B.

Dynavax has worldwide commercial rights to HEPLISAV-B.

About Dynavax

Dynavax, a clinical-stage biopharmaceutical company, discovers and develops novel vaccines and therapeutics in the areas of infectious diseases and oncology. Dynavax's lead product candidates are HEPLISAV-B ™ , a Phase 3 investigational adult hepatitis B vaccine, and SD-101, an investigational cancer immunotherapeutic currently in several Phase 1/2 studies. For more information, visit www.dynavax.com .

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding HEPLISAV-B and FDA review. These statements are subject to a number of risks and uncertainties that could cause actual results to differ materially, including whether there will be changes in the data or interpretation; whether the final study results will be deemed satisfactory by the FDA; whether additional studies or manufacturing process enhancements will be required or other issues will arise that will negatively impact the review and approval by the FDA; initiation, enrollment and completion of pre-clinical studies and clinical trials of our other product candidates, including SD-101; the results of clinical trials and the impact of those results on the initiation or continuation of subsequent trials and issues arising in the regulatory process; and other risks detailed in the "Risk Factors" section of our most recent current periodic report filed with the SEC. These statements represent our estimates and assumptions only as of the date of this press release. We do not undertake any obligation to update publicly any such forward-looking statements, even if new information becomes available. Information on Dynavax's website at www.dynavax.com is not incorporated by reference in our current periodic reports with the SEC.

1 Nelson, J. et al. American Journal of Public Health, "Compliance with Multiple-Dose Vaccine Schedules Among Older Children, Adolescents and Adults: Results from a Vaccine Safety Datalink Study." 2009. Vol. 99 No. S2.

Media Contact: Katie Hogan WCG 415.658.9745 Email contact Investor Contact: Michael Ostrach Chief Financial Officer, Dynavax 510.665.7257 Email contact

Scroll down for more posts ▼

Top 10 Most Recent News Articles

24X Options Filing Puts Earnings Bets Before the SEC

Updated Category News Views 15

An earnings release already turns the market into a bar fight; 24X wants to put part of that fight inside a regulated binary-options contract. The Stamford-based exchange has filed a proposed rule change with the SEC for 24X Options, a facility that would offer a conventional options market alongside contracts tied to company performance targets. It is an interesting...

Continue Reading
SecureSpace Plants a Fifth Flag in Miami Beach Storage

Updated Category News Views 111

A small box on Alton Road may carry outsized weight Miami Beach does not hand out cheap, easy real estate wins, which is why SecureSpace's opening at 633 Alton Road deserves a closer look than its modest footprint might suggest. The newly rebranded SecureSpace Miami Beach facility has 18,358 square feet of traditional storage and locker space spread across 536 units, plus...

Continue Reading
Workday’s EU Cloud Move Raises the Sovereignty Bar Again

Updated Category News Views 27

Europe’s sovereignty squeeze just got a lot more concrete for Workday. The company is taking its EU Sovereign Cloud beyond the usual data-residency talking points by planning an Ireland-based operating company, European leadership, and governance intended to keep decisions on the service and customer data inside Europe. For a platform sitting underneath payroll, HR...

Continue Reading
PSEG Declares $0.67 Fourth-Quarter 2026 Cash Dividend

Updated Category News Views 190

A 67-cent utility dividend rarely sets the tape on fire, and that is precisely the point. Public Service Enterprise Group declared a regular fourth-quarter 2026 common-stock dividend of $0.67 per share, payable on or before December 31 to shareholders of record on December 10. For owners of NYSE:PEG, this is the sort of announcement that belongs in the “steady as she...

Continue Reading
Autoliv's Omni Safety Award Is a Promising Early Signal

Updated Category News Views 34

Reclined car seats are becoming a real engineering headache, not some showroom gimmick, and Autoliv has put a marker down with Omni Safety™. The company received 2026 Automotive News PACE Pilot recognition for the system, which tackles occupant protection when people are sitting farther back than conventional vehicle safety designs assumed. That matters because...

Continue Reading
Apani Adds Kelsun Assets to Its Natural Fiber Platform

Updated Category News Views 141

A materials deal with more chemistry than chest-thumping Seaweed and cotton have landed under one roof, which is a lot more interesting than another apparel brand slapping a green label on ordinary fabric. Apani said November 17 it acquired the assets of Keel Labs, bringing Keel's seaweed-based Kelsun fiber alongside Apani's enhanced cotton-cellulose filament technology....

Continue Reading
Insider Risk Makes Human Judgment a Security Priority

Updated Category News Views 114

A badge, a password, and a locked gate can all look reassuring right up until the person holding them starts to crack. Signpost Six's new report, The Psychology of Insider Risk, lands on an uncomfortable truth: the most consequential security weakness may not be a system at all. It may be an employee under strain, in conflict, in debt, making a mistake, or being quietly...

Continue Reading
Charter’s $1.5 Billion Tender Tests Debt Discipline

Updated Category News Views 247

Debt cleanup arrives with a hard ceiling Eight far-dated bond issues just got a very specific invitation from Charter Communications: hand them over for cash, but do not expect the company to write a blank check. Charter set final pricing on November 17 for tender offers covering up to $1.5 billion in aggregate consideration, excluding accrued interest and deal expenses....

Continue Reading
LG Channels UAE Push Tests the Free Streaming Model

Updated Category News Views 17

A television's idle screen is turning into contested real estate in the UAE. LG Channels is adding programming from Rakuten TV, Stingray and Red Bull TV to its free, ad-supported service, and that matters for more than somebody hunting a movie after dinner. This is a practical push to make webOS-powered screens more useful, more frequently used and, eventually, more...

Continue Reading
MAXHUB's Canon Office Test Puts Hybrid Work on Trial

Updated Category News Views 81

Thirty-nine devices scattered through a new Hong Kong office may not sound earth-shaking, but this is how workplace technology actually earns its keep: not under trade-show lights, but when somebody is late to a meeting in another time zone and the room has to work anyway. MAXHUB and Canon Hong Kong have launched the first officially delivered Co-Create 100 project...

Continue Reading

Top 5 Most Recently Viewed Articles

Lexicon Pharmaceuticals Unveils Q3 Financials and Future Plans

Updated Category News Views 138

Third Quarter Financial Highlights of Lexicon Pharmaceuticals Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) has disclosed its financial performance for the third quarter of 2025, highlighting significant revenue increases attributed primarily to strategic licensing agreements and product sales. Strategic Partnerships and Revenue Growth In an impressive leap, Lexicon's...

Continue Reading
Growing Innovations in Robotic Dentistry to 2034 and Beyond

Updated Category News Views 178

The Rise of Robotic Dentistry and Its Market Growth The shift towards technological integration in the healthcare sector has begun a revolutionary transformation in dental care. The robotic dentistry market is anticipated to grow significantly, projected to increase from USD 617.39 million in 2024 to an approximate USD 2.24 billion by 2034. This acceleration is based on a...

Continue Reading
Chipotle Lawsuit Update: Key Actions for Shareholders

Updated Category News Views 126

Important Information for Chipotle Shareholders Shareholders of Chipotle Mexican Grill, Inc. (NYSE: CMG) are being advised about an ongoing class action lawsuit that could impact their investments. It is vital for all affected shareholders to take note of critical deadlines and actions they need to undertake to ensure their rights and potential recoveries are protected....

Continue Reading
Quisitive Technology Solutions Reports Q2 2024 Financial Results

Updated Category News Views 144

Quisitive Reports Second Quarter 2024 Financial Results Quisitive Technology Solutions Inc. (“Quisitive” or the “Company”) (TSXV: QUIS, OTCQX: QUISF), a leading provider of Microsoft Cloud and AI solutions, has announced its financial results for the second quarter ending June 30, 2024. Management Commentary Quisitive's CEO, Mike Reinhart, commented, “The first...

Continue Reading
Natural Grocers Reports Strong Fiscal 2024 Performance

Updated Category News Views 231

Natural Grocers by Vitamin Cottage Sees Remarkable Growth in Fiscal 2024 Natural Grocers by Vitamin Cottage, Inc. (NYSE: NGVC) has unveiled its financial results for the fourth quarter and full year of fiscal 2024. The report highlights significant sales and earnings achievements, showcasing the company’s robust performance in a competitive grocery market. Exceptional...

Continue Reading